Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HCW Biologics Inc.HCWB · Entity 8172 | SVP of Business Development | July 29, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HCW Biologics Inc.
Report date July 29, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,691 |
Reported balance
After 2026-07-29 transaction · row 1
1 source rowRow 1 · 2026-07-29 · Purchase · Acquired 7,736 · Balance 8,691 F1: The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 7,736 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 7,736 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 31, 2026 20:06 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 7,736 | $2.59 | $19,997.56 |
DisclosureSEC source: 0001493152-26-035631 · ownership.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,691 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement under a Securities Purchase Agreement dated July 29, 2026 ("SPA"), which purchase is exempt from the registration requirements of Section 5 of the Securities Exchange Act of 1934, as amended, pursuant to Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D thereunder. Additionally, the reporting person is entitled to receive common warrants exercisable for an aggregate of up to 7,736 shares of common stock. Under the terms of the SPA, issuance of the common warrants is subject to stockholder approval under Nasdaq Listing Rule 5635(d). Upon issuance, the common warrants will be exercisable immediately and expire 5.5 years from date of issuance. Read SEC document |
| May 08, 2025 Filed May 9, 2025 21:29 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 962 | $26.00 | $25,012.00 |
DisclosureSEC source: 0000950170-25-068275 · ownership.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,720 F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. Read SEC document |
| May 07, 2025 Filed May 9, 2025 21:29 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock Purchase Warrant · Derivative | 481 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0000950170-25-068275 · ownership.xml · derivative · entry 2 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481 Underlying: Common Stock · 481 shares Expires 2030-05-07 F1 · kind: These shares are being issued as a portion of and pursuant to the Company entering into a definitive conversion agreement on May 1, 2025, with a conversion date of May 7, 2025, along with 13 other holders of $6.6 million of the outstanding principal of the Secured Notes to convert the Secured Notes for an aggregate of 253,083 shares of the Company's Common Stock at a conversion price of $26.00 per share (on a post-reverse split basis), issuance of an aggregate of 126,540 warrants each exercisable for one share of Common Stock at an exercise price of $26.00 per share (on a post-reverse split basis), and a portion of the 2,174,311 shares of Wugen Inc. common stock held by the Company. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 19:20 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantCommon Stock | 71,429 | $1.40 | $100,000.60 |
DisclosureSEC source: 0001209191-24-003783 · doc4.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,238 F1 · kind: The reporting person purchased these shares directly from the issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d) promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 21:56 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,501 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-23-058081 · doc4.xml · derivative · entry 2 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,501 shares Expires 2029-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 20% of the total shares subject to the stock option grant vested on September 16, 2020; 20% of the total shares subject to the stock option grant vested on September 16, 2021; 25% of the total shares subject to the stock option grant vested on September 16, 2022; and 35% of the total shares subject to the stock option grant vested on September 16, 2023. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 21:56 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 7,501 | $0.14 | $1,050.14 |
DisclosureSEC source: 0001209191-23-058081 · doc4.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2023 Filed Jun 10, 2023 00:00 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,356 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-23-036087 · doc4.xml · derivative · entry 3 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,501 Underlying: Common Stock · 5,356 shares Expires 2029-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 20% of the total shares subject to the stock option grant vested on September 16, 2020; 20% of the total shares subject to the stock option grant vested on September 16, 2021; 25% of the total shares subject to the stock option grant will vest on September 16, 2022; and 35% of the total shares subject to the stock option grant will vest on September 16, 2023. Read SEC document |
| June 08, 2023 Filed Jun 10, 2023 00:00 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 10,000 | $2.16 | $21,574.00 |
DisclosureSEC source: 0001209191-23-036087 · doc4.xml · nonDerivative · entry 2 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,308 Read SEC document |
| June 08, 2023 Filed Jun 10, 2023 00:00 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 5,356 | $0.14 | $749.84 |
DisclosureSEC source: 0001209191-23-036087 · doc4.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 17:10 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,285 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001209191-21-067740 · doc4.xml · derivative · entry 2 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,857 Underlying: Common Stock · 4,285 shares Expires 2029-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 20% of the total shares subject to the stock option grant vested on September 16, 2020; 20% of the total shares subject to the stock option grant vested on September 16, 2021; 25% of the total shares subject to the stock option grant will vest on September 16, 2022; and 35% of the total shares subject to the stock option grant will vest on September 16, 2023. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 17:10 UTC | HCW Biologics Inc. HCWB · Entity 8172 | Exercise / conversionCommon Stock | 4,285 | $0.14 | $599.90 |
DisclosureSEC source: 0001209191-21-067740 · doc4.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 21:46 UTC | HCW Biologics Inc. HCWB · Entity 8172 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-055528 · doc4.xml · derivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-09-07 F1 · derivative.exercise_date: The option will vest as follows: 20% will vest on September 8, 2022, 20% will vest on September 8, 2023, 25% will vest on September 8, 2024 and 35% will vest on September 8, 2025. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 21:05 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 5,605 | $3.95 | $22,156.57 |
DisclosureSEC source: 0001209191-21-053170 · doc4.xml · nonDerivative · entry 2 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,667 Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 21:05 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 7,853 | $4.08 | $32,069.30 |
DisclosureSEC source: 0001209191-21-053170 · doc4.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,062 F1 · price: The range of prices for the shares of Common Stock is from $4.06 to $4.166. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 23:53 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 10,532 | $4.25 | $44,785.22 |
DisclosureSEC source: 0001209191-21-053050 · doc4.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,209 F1 · price: The range of prices for the shares of Common Stock is from $4.2519 to $4.27. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| August 19, 2021 Filed Aug 24, 2021 21:01 UTC Amendment | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 10,532 | $4.29 | $45,218.09 |
DisclosureSEC source: 0001209191-21-053163 · doc4a.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,209 F1 · price: The range of prices for the shares of Common Stock is from $4.293 to $4.31 The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities purchased at each separate price. Read SEC document |
| July 22, 2021 Filed Jul 23, 2021 23:29 UTC | HCW Biologics Inc. HCWB · Entity 8172 | PurchaseCommon Stock | 31,250 | $8.00 | $250,000.00 |
DisclosureSEC source: 0001209191-21-048080 · doc4.xml · nonDerivative · entry 1 Flowers Lee · CIK 0001866254 · SVP of Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,677 F1 · shares: Represents shares of Common Stock purchased jointly by Lee and Wendy Flowers. F2 · shares: Represents shares of Common Stock purchased in connection with the Issuer's initial public offering for consideration of $8.00 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.